|15 FEBRUARY 2012|
- María Blasco, Chief Scientific Advisor, Life Length, among the inventors
- The most precise technique in the world to measure short telomeres
The Spanish National Cancer Research Centre (CNIO) has obtained a patent from the U.S. Patent and Trademark Office for its method of measuring telomeres known as Telomapping (United States Patent Nº 8,084,203 B2, date of patent December 27, 2011). Life Length, the leading telomere testing and services company, reached an exclusive agreement with the CNIO at the end of 2010 to be the sole user of said technology via royalties.
Specifically, the technology known as Telomapping determines the length of telomeres of every single cell in biopsies and all manner of tissues, such as skin. The invention relates to methods and reagents for the determination of telomere length in tissue sections by the single cell telomeric mapping technique based on a fluorescent in situ hybridization step using a telomerespecific probe and an interpolation step using a standard curve correlating fluorescent intensity and telomere length obtained from a collection of cell lines of known telomere length.
The invention further relates to methods for the identification of stem cell niches within tissues and for the identification of compounds capable of triggering stem cell mobilization using the telomere length as criteria for the identification of stem cells and which rely on the single cell telomeric mapping technique of the invention. Life Length commercializes this technique that measures every telomere individually, cell by cell, with enormous precision and thereby provides information about short telomeres at the individual cell level which is critically important in the fields of cellular senescence and aging.
This is the most advanced technique in the world and it is only available through Life Length. Telomere tests can be of great significance within the context of generic tests since they can help to determine and be predictive of the appearance of different diseases, such as cancer and cardiovascular disorders. The granting of the U.S. patent coincides with the agreement between Life Length and Cenegenics Medical Institute, the largest group of preventive medicine in the United States, to provide the telomere test to its more than 20,000 patients.